Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

SESN

Sesen Bio (SESN)

Sesen Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SESN
DateTimeSourceHeadlineSymbolCompany
10/08/202321:30PR Newswire (US)Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SESNSesen Bio Inc
07/03/202304:41Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
07/03/202304:35Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
04/03/202303:07Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:SESNSesen Bio Inc
04/03/202303:06Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:SESNSesen Bio Inc
03/03/202304:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
03/03/202303:32Business WireSesen Bio Stockholders Approve Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
01/03/202300:08Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
01/03/202300:03Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SESNSesen Bio Inc
01/03/202300:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
01/03/202300:00Business WireSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsNASDAQ:SESNSesen Bio Inc
28/02/202308:33Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
28/02/202300:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
22/02/202301:05Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
22/02/202301:00Business WireLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With CarismaNASDAQ:SESNSesen Bio Inc
18/02/202300:18Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
18/02/202300:08Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
18/02/202300:04Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
18/02/202300:02Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
17/02/202309:06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SESNSesen Bio Inc
17/02/202308:46Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
17/02/202308:42Business WireLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingNASDAQ:SESNSesen Bio Inc
17/02/202300:02Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
17/02/202300:00Business WireSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerNASDAQ:SESNSesen Bio Inc
16/02/202308:55Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SESNSesen Bio Inc
16/02/202300:02Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
16/02/202300:00Business WireBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
15/02/202308:40Edgar (US Regulatory)Registration Pursuant to Securities Act Rule 462(b) of up to an Additional 20% of Securities for an Offering That Was Registered on a Form S-4 (s-4mef)NASDAQ:SESNSesen Bio Inc
15/02/202301:08Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
15/02/202300:00Business WireSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerNASDAQ:SESNSesen Bio Inc
 Showing the most relevant articles for your search:NASDAQ:SESN